ArticleJournal of cancer immunology2025
Highlighting the Role of DCLK1 in Tumor Invasion and Potential for Therapeutic Intervention.
Article in Journal of cancer immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
Abstract
Head and neck squamous cell carcinoma (HNSCC) accounts for nearly 5% of global cancer deaths per year, with epidemiological studies suggesting an expected 30% increase in cases by 2030 due to rising incidence of viral infection (i.e. huma papilloma virus [HPV]). Treatment consists primarily of surgical tumor removal accompanied by post-operative chemoradiation therapy; however, disease recurrence is still an issue amongst 10-26% of patients. Doublecortin-like kinase 1 (DCLK1) is a microtubule-associated protein with dual kinase activity, and upregulation has been associated with poor prognosis in multiple solid tumors. Recent studies by Arnold
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.